Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
DeGaulle I Chigbu, Alissa M Coyne Pennsylvania College of Optometry Salus University, Elkins Park, PA, USA Abstract: Allergic disorders of the ocular surface are primarily characterized as IgE- and/or T-lymphocyte-mediated disorders that affect the cornea, conjunctiva, and eyelid. Approxi...
Guardado en:
Autores principales: | Chigbu DI, Coyne AM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/27cecb65ac864007837c2d4c0b4bf021 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Jack V Greiner, et al.
Publicado: (2011) -
Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials
por: Ciolino JB, et al.
Publicado: (2015) -
Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra RP, et al.
Publicado: (2019) -
Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
por: Bergmann MT, et al.
Publicado: (2014) -
Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
por: Patricia B Williams, et al.
Publicado: (2010)